Baljinder Bhullar
CIK: 0001401225
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Bhullar Baljinder
Bhullar Baljinder (SEC CIK 0001401225) files insider reports with the SEC as Director of Lexaria Bioscience Corp. (LEXX) and Chief Financial Officer of Damon Inc. (DMN).
Signal8 holds 3 ownership filings by Bhullar Baljinder (2 Form 3, 1 Form 4), filed between Nov 15, 2024 and May 16, 2025. Those filings report 1 transaction, the latest on May 15, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Bhullar Baljinder's filings is in VANCOUVER, A1.
Recent filings by Bhullar Baljinder
- May 15, 2025: Grant or award of LEXX derivative securities (Form 4, code A).
Other insiders filing for Lexaria Bioscience Corp. (LEXX)
- BUNKA CHRISTOPHER, Director
- DOCHERTY JOHN MARTIN, President
- Carle Vanessa, Secretary
- CHRISTOPHER RICHARD, Chief Executive Officer
- Shankman Michael Elliot, Chief Financial Officer
- Baxter Nicholas W, Director